SEC EDGARSEP 111 min read$CBLL

Woo Raymond sold $119K of CBLL

Woo Raymond (Chief Technology Officer) sold 4,887 shares of Ceribell, Inc. (CBLL) at $24.33 ($0.12M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Woo Raymond

Published Sep 11, 2026, 12:23 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CBLL

Neutral

high confidence

Mentioned

$CBLL

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CBLLNeutralLow

Why it matters

The sale represents a modest reduction in insider holdings and is unlikely to affect investor sentiment.

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

What to watch

Potential upcoming product milestones or financing events not disclosed.

Relevance 3/10Novelty 5/10Timing: today

Background

Form 4 filings provide transparent disclosure of insider trades; this sale is pre‑arranged under a 10b5‑1 plan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CBLLNeutralHigh confidence

Context

CTO Woo Raymond sold 4,887 shares of Ceribell for $118,900 via a 10b5‑1 plan.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

Sale size is small relative to total holdings and market cap; no immediate market reaction expected.

Market effects

Sector

None; Ceribell operates in niche medical device space with limited sector impact.

Regional

None; transaction is company‑specific.

Global

None

Counterpoint

What could challenge this read

Insider sale could be a routine liquidity move, not a negative signal.

Key entities

Company
Ceribell, Inc.
Medical device company developing seizure detection technology.
Executive
Woo Raymond
Chief Technology Officer of Ceribell.

Read at source ← All news

SEP 17

$BLSMHighAI 8/10

Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG

Biotech stocks BLSM, NEOG, ILMN, CBLL, and ADPT hit 52-week highs. BLSM rose 18% on positive trial data, NEOG grew 2% with Q4 revenue of $225M, ILMN reached $236 on 9.5% Q2 growth, CBLL hit $25.63 with Q2 revenue up 33%, and ADPT climbed 3% with full-year revenue forecast between $268M-$278M.

rttnews.com3 min

AUG 15

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.com7 min

AUG 10

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor

SEC EDGAR 8-K6 min

AUG 10

$CBLLMedAI 8/10

Ceribell Secures FDA Clearance For Advanced EEG AI Enhancements

Ceribell (CBLL) said the U.S. FDA granted 510(k) clearance for two AI enhancements in its cloud Neurology Portal: epileptiform abnormality detection and artifact reduction. The company says the updates improve EEG signal interpretation and reduce review time. CBLL shares closed Aug. 7, 2026 at $18.81, up 3.07%.

rttnews.com4 min

AUG 3

$CBLLMedAI 8/10

CeriBell stock rises after securing Medicare payment approval

CeriBell Inc. (NASDAQ:CBLL) shares rose about 3% after CMS approved a New Technology Add-on Payment for its Delirium Monitor System. The NTAP allows up to $2,171 per eligible Medicare patient case, starting Oct. 1, 2026, following FDA 510(k) clearance in Dec. 2025.

investing.com3 min

MAY 26

$CBLLMed

Manni Joseph S. sold $25K of CBLL

Manni Joseph S. (Chief Revenue Officer) sold 1,378 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21.

SEC EDGAR2 min